Compositions And Methods For Glycosylating Cannabinoid Compounds
The present invention relates generally to the use of novel UDP-glucosyltransferases enzymes having specific activity towards cannabinoid compounds. The present invention further relates generally to the use of novel UGT enzymes having specific activity towards cannabinoid compounds to generate water-soluble cannabinoid glycoside compounds.
1 . A method for producing select water-soluble cannabinoid compounds comprising the step of:
providing a yeast cell expressing a heterologous nucleotide sequence, operably linked to a promoter, encoding a UDP-glucosyltransferases (UGT) having glycosylation activity towards a cannabinoid having at least one glycosylation site selected from the group consisting of: cannabidiol (CBD), cannabidiolic acid (CBDA), delta-9-tetrahydrocannabinol (THC), tetrahydrocannabinolic acid (THCA); cannabigerol (CBG), and cannabigerolic acid (CBGA);
introducing said cannabinoid having at least one glycosylation site to said yeast cell; and
glycosylating said cannabinoid forming a cannabinoid glycoside.
2 . The method of claim 1 , wherein said step of introducing comprises the step of introducing said cannabinoid having at least one glycosylation site to a yeast cell culture.
3 . The method of claim 1 , wherein said UGT comprises a UGT selected from the group consisting of: SEQ ID NOs. 1-9181.
4 . The method of claim 1 , wherein said yeast cell comprises a yeast cell selected from the group consisting of: a Pichia pastoris cell, a Saccharomyces cerevisiae cell, and a Kluyveromyces marxianus cell.
5 . The method of claim 1 , wherein said nucleotide sequence encoding a heterologous UGT is codon optimized for expression in a yeast cell.
6 . A method for producing water-soluble cannabinoid compounds comprising:
providing a yeast cell expressing a heterologous nucleotide sequence, operably linked to a promoter, encoding a UDP-glucosyltransferases (UGT) having glycosylation activity towards a cannabinoid;
introducing said cannabinoid having at least one glycosylation site to said yeast cell;
glycosylating said cannabinoid forming a cannabinoid glycoside; and
wherein said cannabinoid having at least one glycosylation site is selected from the group consisting of: delta-Δ 9 -tetrahydrocannabinol (THC), delta-Δ8-tetrahydrocannabinol (Delta-8-THC), 11-Hydroxy-Δ 9 -tetrahydrocannabinol (11-OH-THC), tetrahydrocannabinolic acid (THCA), cannabidiol (CBD), cannabichromene (CBC), cannabigerol (CBG), cannabigerolic acid (CBGA), cannabinol (CBN), cannabidiolic acid (CBDA), cannabidiolic acid (CBDA), cannabicyclol (CBL), cannabivarin (CBV), tetrahydrocannabivarin (THCV), cannabigerivarin (CBGV), cannabichromevarin (CBCV), cannabidivarin (CBDV), cannabicyclol (CBL), cannabielsoin (CBE), cannabifuran (CBF); and cannabinodiol (CBDN).
7 . The method of claim 6 , wherein said step of introducing comprises the step of introducing said cannabinoid having at least one glycosylation site to a yeast cell culture.
8 . The system of claim 6 , wherein said UGT comprises a UGT selected from the group consisting of: SEQ ID NOs. 1-9181, SEQ ID NO. 9188, SEQ ID NO. 9208, SEQ ID NO. 9210, SEQ ID NO. 9212, SEQ ID NO. 9214, SEQ ID NO. 9216, SEQ ID NO. 9218, SEQ ID NO. 9220, SEQ ID NO. 9236, SEQ ID NO. 9238, SEQ ID NO. 9240, SEQ ID NO. 9242, and SEQ ID NO. 9244.
10 . The system of claim 6 , wherein said yeast cell comprises a yeast cell selected from the group consisting of: a Pichia pastoris cell, a Saccharomyces cerevisiae cell, and a Kluyveromyces marxianus cell.
11 . The system of claim 6 , wherein said bioreactor comprises a fermenter.
11 . The system of claim 6 , wherein said nucleotide sequence encoding a heterologous glycosyltransferase is codon optimized for expression in a yeast cell.
12 . A method of glycosylating a cannabinoid comprising the steps of:
providing a UDP-glucosyltransferases (UGT) having glycosylation activity towards a cannabinoid, wherein said UGT is selected from the group consisting of: SEQ ID NOs. 1-9181, and SEQ ID NO. 9208, SEQ ID NO. 9210, SEQ ID NO. 9212, SEQ ID NO. 9214, SEQ ID NO. 9216, SEQ ID NO. 9218, SEQ ID NO. 9220, SEQ ID NO. 9236, SEQ ID NO. 9238, SEQ ID NO. 9240, SEQ ID NO. 9242, and SEQ ID NO. 9244; and
introducing a cannabinoid having at least one glycosylation site to said UGT having glycosylation activity towards said cannabinoid forming a cannabinoid glycoside.
13 . The method of claim 12 , wherein said cannabinoid having at least one glycosylation site is selected from the group consisting of: cannabidiol (CBD), cannabidiolic acid (CBDA), delta-9-tetrahydrocannabinol (THC), and tetrahydrocannabinolic acid (THCA).
14 . The method of claim 12 , wherein said cannabinoid having at least one glycosylation site is selected from the group consisting of: delta-Δ 9 -tetrahydrocannabinol (THC), delta-Δ8-tetrahydrocannabinol (Delta-8-THC), 11-Hydroxy-Δ 9 -tetrahydrocannabinol (11-OH-THC), tetrahydrocannabinolic acid (THCA), cannabidiol (CBD), cannabichromene (CBC), cannabigerol (CBG), cannabigerolic acid (CBGA), cannabinol (CBN), cannabidiolic acid (CBDA), cannabidiolic acid (CBDA), cannabicyclol (CBL), cannabivarin (CBV), tetrahydrocannabivarin (THCV), cannabigerivarin (CBGV), cannabichromevarin (CBCV), cannabidivarin (CBDV), cannabicyclol (CBL), cannabielsoin (CBE), cannabifuran (CBF); and cannabinodiol (CBDN).
15 . The method of claim 12 , wherein said step of introducing comprises the step of introducing selected from the group consisting of:
introducing a cannabinoid having at least one glycosylation site to a UGT having glycosylation activity towards said cannabinoid forming a cannabinoid glycoside, in an in vitro system;
introducing a cannabinoid having at least one glycosylation site to a UGT having glycosylation activity towards said cannabinoid forming a cannabinoid glycoside, in an ex vivo system; and
introducing a cannabinoid compound to a UGT having glycosylation activity towards said cannabinoid forming a cannabinoid glycoside, in an in vivo system.
16 . The method of claim 15 , wherein said ex vivo system comprises a bioreactor system.
17 . The method of claim 15 , wherein said in vitro system comprises a synthetic cannabinoid synthesis system.
18 . The method of claim 15 , wherein said in vivo system comprises an in vivo system selected from the group consisting of: a Cannabis plant or part thereof, and a cell culture.
19 . The method of claim 18 , wherein said cell culture is selected from the group consisting of: a yeast cell culture, a bacterial cell culture, an algal cell culture, a fungi cell culture, and a plant cell culture.
20 . The method of claim 19 , wherein said yeast cell cultures comprises a yeast cell culture selected from the group consisting of: a Pichia pastoris cell culture, a Saccharomyces cerevisiae cell culture, and a Kluyveromyces marxianus cell culture.